| Psoriasis
Ilumya vs Bimzelx
Side-by-side clinical, coverage, and cost comparison for psoriasis.Deep comparison between: Ilumya vs Bimzelx with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBimzelx has a higher rate of injection site reactions vs Ilumya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bimzelx but not Ilumya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ilumya
Bimzelx
At A Glance
SC injection
Every 12 weeks
IL-23 antagonist
SC injection
Every 4-8 weeks
IL-17A and F antagonist
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Non-Radiographic Axial Spondyloarthritis
- Ankylosing spondylitis
- Hidradenitis Suppurativa
Dosing
Psoriasis vulgaris 100 mg SC at Weeks 0, 4, and every 12 weeks thereafter.
Psoriasis vulgaris 320 mg SC at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter; for patients weighing 120 kg or more, consider 320 mg every 4 weeks after Week 16.
Arthritis, Psoriatic, Non-Radiographic Axial Spondyloarthritis, Ankylosing spondylitis 160 mg SC every 4 weeks; for Arthritis, Psoriatic with coexistent moderate to severe plaque psoriasis, use the plaque psoriasis dosing regimen.
Hidradenitis Suppurativa 320 mg SC at Weeks 0, 2, 4, 6, 8, 10, 12, 14, and 16, then every 4 weeks thereafter.
Contraindications
- Previous serious hypersensitivity reaction to tildrakizumab-asmn or any excipient
—
Adverse Reactions
Most common (>=1%) Upper respiratory infections, injection site reactions, diarrhea
Serious Hypersensitivity reactions, infections
Most common (>=1%) Upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, fatigue, diarrhea, urinary tract infection
Serious Suicidal ideation and behavior, serious infections, liver biochemical abnormalities, inflammatory bowel disease
Postmarketing Conjunctivitis, esophageal candidiasis
Pharmacology
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor, thereby suppressing the release of proinflammatory cytokines and chemokines.
Bimekizumab-bkzx is a humanized IgG1 monoclonal antibody that selectively binds IL-17A, IL-17F, and IL-17AF cytokines, inhibiting their interaction with the IL-17 receptor complex and suppressing the release of proinflammatory cytokines and chemokines.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ilumya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Bimzelx
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Ilumya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Bimzelx
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (5/8)
Humana
Ilumya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Bimzelx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
$15/fillfill
Bimzelx BridgeCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IlumyaView full Ilumya profile
BimzelxView full Bimzelx profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.